DNAprint Genomics (DNAG)

[IVRT]

spook, I do not disagree with the loss, but we are all aware as you for sometime, that DNAP is a Speculative venture in the development phase. Consequently, DNAP does not have a cash flow positive environment at this point in time. What pray tell are you trying to get at? Research and development costs cash, and the last time I looked people did not work for free in corporate America. Executives today corner some hefty salaries, good or bad, why should DNAP be any different? It is quite possible that the 7 players at DNAP are making below industry averages. Certainly, some are not going to cash in their stock options and awards tomorrow due to restrictions.

Debt goes hand in hand with R & D.
IVRT